<DOC>
	<DOCNO>NCT00960726</DOCNO>
	<brief_summary>The goal clinical research study learn NOV-002 help restore bone marrow blood level patient MDS . The safety drug also study .</brief_summary>
	<brief_title>NOV-002 Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>The Study Drug : NOV-002 type blood cell production stimulate drug . NOV-002 believe stimulate bone marrow increase production mature cell bloodstream , include red white blood cell platelet . Screening Tests : Signing consent form mean able take part study . You `` screen test '' help doctor decide eligible take part study . The following test procedure perform : - Your medical history record . - You ask drug take may take . - You physical exam , include measurement weight vital sign ( blood pressure , temperature , breathe rate , heart rate ) . - Urine collect routine test . - Blood ( 7 teaspoon ) draw routine test check HIV hepatitis B C. - If bone marrow aspiration month screen test , one perform check status disease . To collect bone marrow aspirate , area hip numb anesthetic , small amount bone marrow withdrawn large needle . - Women able become pregnant pregnancy test part routine blood urine collection . To take part study , pregnancy test must negative . The study doctor discus screen test result . If screening test show eligible take part study , enrol . Other treatment option discuss . Study Drug Administration : If find eligible take part study , receive study drug NOV-002 needle skin 1 time day study . The study staff teach and/or caregiver inject study drug . The study staff also give write copy instruction inject study drug . You give diary card record body inject study drug , well side effect may occur . If miss dose study drug , note diary card take study drug next day schedule . You take double , `` make-up '' dose time . You must store study drug refrigerator reach child . You ask bring leftover study drug study visit . Study Visits : - You study visit 1 time week Weeks 1-8 1 time month Months 3-12 . At visit , follow test procedure perform : - You ask drug take may take side effect may experience . - Your vital sign measure . - Blood ( 5 teaspoon ) draw routine test . - You physical exam 1 time month study . - You bone marrow aspiration every 3 month study check status disease . Length Study : You take study drug 12 month . You take study intolerable side effect , disease get bad , doctor think best interest . Long-Term Follow-Up : After finish take study drug reason , follow procedure perform 12 month , stop start receive different treatment disease get bad : Blood ( 5 teaspoon ) draw routine test 1 time month . You bone marrow aspiration every 3 month . This investigational study . NOV-002 FDA approve commercially available . At time , use research . Up 40 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . Age great equal 18 year 2 . Women childbearing potential men whose partner childbearing potential must willing use acceptable method birth control trial participation surgically sterile woman postmenopausal ( define menstrual cycle great two year ) . Acceptable method birth control : cervical cap diaphragm spermicide , condom , oral birth control pill , intrauterine device ( IUD ) , implant injectable birth control . 3 . The patient must ability understand willingness sign write informed consent form agree abide trial restriction return require assessment 4 . The patient must able self administer daily subcutaneous injection caregiver must able administer daily subcutaneous injection 5 . Has diagnosis myelodysplastic syndrome IPSS score less equal 1 6 . Documented cytopenias persistent 2 month define : Red cell transfusion dependence define receive 4 unit red cell within period 8 week anemia hemoglobin less 9 gm/dL ; and/or Untransfused hemoglobin 10 gm/dL less two occasion great equal 1 week apart ; and/or Platelet count le 50 x 10 ( 9 ) /dL two occasion great equal 1 week apart ; and/or Neutropenia define ANC le 1 x 10 ( 6 ) /dL two occasion great equal 1 week apart . 7 . Adequate organ function define : Bilirubin le equal 2.5 mg/dL ( unless clearly attributable hemolysis ) ; Creatinine le equal 2mg/dL calculated creatinine clearance great 50 ml/min ; AST ALT less 3 time upper limit institutional normal ( ULN ) . 8 . Must discontinue growth factor period 3 week prior enrollment 9 . Up one prior conventional experimental therapy MDS ( include growth factor transfusion ) allow must washout 4 week prior enrollment therapy ( example include lenalidomide , hypomethylating agent etc . ) 1 . Pregnant female nursing mother 2 . Active second malignancy exclude carcinoma insitu uterine cervix , basal squamous cancer skin 3 . Active hepatitis B C infection 4 . Known HIV positive 5 . On oral steroid ( prednisone equivalent ) great 10 mg/day 6 . NOV002 contraindicate patient know hypersensitivity component NOV002</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>NOV-002</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
</DOC>